We would love to hear your thoughts about our site and services, please take our survey here.
LD have some interesting manufactuer products .
https://www.launchdiagnostics.com/manufacturer/fujirebio/
"Launch Diagnostics LimitedLaunch Diagnostics Limited
1,417 followers1,417 followers
17h • 17h •
At Launch Diagnostics, we are a distributor of Fujirebio products (leaders in testing for Neurodegenerative diseases).
Please visit https://lnkd.in/etfKQG5b or contact your local territory
---------------------
https://www.fujirebio.com/en/about-fujirebio
A proven pioneer and partner to the diagnostics industry
Fujirebio is an R&D-driven company constantly developing new technologies and unique biomarkers with high clinical value. Our group mission is to create new value in healthcare and thereby contribute to human health and the future of medical care.
Our global teams located in Japan, Asia, Europe and the US focus on delivering products with the highest quality standards to our customers and partners. We value partnerships with other leading companies in the industry, sharing knowledge, capabilities, and critical materials in order to supply, develop or manufacture diagnostic solutions on a wide variety of platforms. Through this business model, we ensure that the potentially life-changing diagnostic markers meet the largest global need in the shortest possible time."
"
Fujirebio EuropeFujirebio Europe
6,932 followers6,932 followers
22h • 22h •
🤝 Fujirebio is excited to join the AD-RIDDLE project, a groundbreaking hashtag#collaboration between 24 partners to bridge the gap between hashtag#Alzheimer’s research, implementation science, and precision medicine ❤️ "
Good Morning : Pity no mention of "Avacta’s proprietary pre|CISION™ technology platform is enabling first-in-class cancer therapies that boost efficacy and minimise off-target toxicity."
However maybe " one day soon" little Avacta will get recognised as having a ready made solution .
-----------------
"“If we can define appropriate tumor drivers and target them as early as possible, we might be able to think about curing cancer rather than simply controlling it,” she said. "
"“These are very, very exciting times for precision medicine and cancer drug development.”
https://www.aacr.org/blog/2024/01/30/experts-forecast-2024-part-3-precision-medicine-for-cancer-treatment/?utm_medium=twitter&utm_source=social&sf185974604=1
Good Morning courtesy of twitter : Lots of Biotech cash , just a matter of who & when will take the plunge on Avacta .
https://twitter.com/BioStockAnalyst/status/1752029718688219599/photo/1
---------------------
"Jake Weber
@BioStockAnalyst
·
15h
Big Pharma’s patent cliff issue getting mainstream media attention,
Top 20 biopharma have $180 bil in sales at risk from patent expirations by 2028 according to EY
@EYnews
,
But that estimate could prove low compared to…(1/6) 🧵👇
$XBI $IBB
h/t
@cnbc
Show more
Jake Weber
@BioStockAnalyst
·
15h
Bloomberg Intelligence
@business
estimates 170 drugs w/ close to $400 bil in est global sales could lose patent excl by start of next decade,
Big Pharma wants to avoid stagnant rev growth like last patent cliff in 2010…(2/6) 👇
$XBI $IBB
h/t
@byjongardner
@biopharmadive
Show more
Jake Weber
@BioStockAnalyst
·
15h
Big Pharma’s like $BMY which has two of its key drugs, Eliquis and Opdivo, losing patent protection in 2026-2028,
Those two drugs generated +$20 bil in 2022 sales or 43% of BMY’s total sales that year, which is why…(3/6) 👇
$XBI $IBB
h/t
@annikakimc
@cnbc
Show more
Jake Weber
@BioStockAnalyst
·
15h
$BMY spent $22.9 bil to acquire 3 biotechs ( $MRTX, $KRTX, $RYZB) in Q4 23,
Peak sales for lead programs of 3 buyouts are proj at about $8.3 bil...or less than half $20 bil rev at risk from patent expiry by 2028,
BMY's pipeline has more rev potential but still work to do to…
Show more
Jake Weber
@BioStockAnalyst
Big Pharma spent $178 bil on M&A in 2023,
But Stifel estimates the top 16 Big Pharma still have over $500 bil in firepower for more deals,
And
@iqvia_biotech
estimates another $180-$200 bil in biotech M&A this year, so …(5/6) 👇
LD don't say if involved with the pilot but perhaps future opportunity .
Hospital screens for syphilis in country first
https://www.linkedin.com/feed/update/urn:li:activity:7157683333777231873/
"Launch Diagnostics LimitedLaunch Diagnostics Limited
1,418 followers1,418 followers
5h • 5h •
Syphilis is going through a major re-emergence with diagnoses increasing from 7543 in 2021 to 8,692 in 2022, a 15.2% jump and representing the largest annual number of cases reported since 1948 (Gov.uk)
The James Cook Hospital has launched a pilot scheme to screen for syphilis infections in 19–70 year-olds, which will also include testing for HIV, Hepatitis B and C. If the pilot scheme is successful, syphilis screening could be rolled out across the UK. https://lnkd.in/eUZEC2eU
Launch Diagnostics offers a full portfolio of assays and instruments for syphilis testing.
For more information, please visit www.launchdiagnostics.com
------------------
The hospital is offering syphilis screening for adults
Serena Farrow
BBC Tees Reporter
Published
16 January 2024
A Tees hospital has launched the country's first pilot programme for syphilis screening for adults.
The James Cook University Hospital is offering the services to 19 to 70-year-olds who already have their blood sampled at the hospital's A&E department.
The pilot will run for eight weeks from January, and also include routine testing for HIV, Hepatitis B and C.
Patients are informed if they are receiving a test for blood-borne viruses but can decline if they wish.
Outside James Cook Hospital
Image caption,
The test identifies people with undiagnosed infections
“As well as contributing towards national targets to eliminate hepatitis C and HIV, this will be the first pilot programme nationally to include syphilis screening and may help to establish whether this is worth including in other ED screening programmes around the UK," said the hospital's clinical director David Chadwick.
If a patient has received a positive result, they will be contacted to arrange an appointment to discuss the next steps.
However, if they do not hear anything within 28 days, they can assume their tests to be negative.
The test has been successful in identifying people with undiagnosed infections, as well as people with these infections who are not receiving treatment.
Emergency department consultant Catriona Lane said it was great to be "able to help link our emergency department into such an important programme."
“It will not only help us to identify new patients but also those who may have dropped off the system and help give them the treatment they need," she said
The Future of FAPI Therapy - Evident Avacta miles ahead & have all the answers .
https://www.youtube.com/watch?v=C_VP9E1QDdQ
Coris stand advertising AMR tests
https://www.linkedin.com/company/coris-bioconcept/
Suspect AVCT market cap value today higher than 2016 - o/s not that important - However what matters is what the Asset IP will be worth - best to look forward not back . IMO .
https://avacta.com/investors/share-price-analysis/
Could be right Pennyfortheguy : Avacta seem to have replaced CMO-CSO-CDO positions with just one "Head of Research and Development, overseeing all clinical development and pre-clinical research activities of the Therapeutics Division."
Avacta must feel confident they can progress AVA6000 & AVA3996 though the clinic without the need for Fiona McL /N.Bell development /scientific expertise . Personally think both those asssets will kept inhouse & taken all the way through to commercialisation by Avacta ( they can outsource marketing/manufacturing /product delivery etc )
To do so obviously requires new funding :
Few options to be considered :
One buyer takes over Avacta Therapeutics and shaeholders get a investment return .-
or
Funding will come from new licence/royalty deals with external parties / They will take new pre|CISIONTM technology prodrugs with the responsibility for pre/post clinical activities & comercialisation .. Avacta can provide consultancy services
and/or Plus if required other funding persued from key biotech investors and/or moving to NASDAQ .
Affimers could also follow the same approach (already happening with partners )
One thing for sure could be a very exciting 2024.
Think Fiona already found a new part time role : Wish her well in finding new ways to treat cancer .
https://www.hoxtherapeutics.com/targets/hox/
https://www.hoxtherapeutics.com/board/fiona-mclaughlin/
https://uk.linkedin.com/in/fmclaughlin
"Source Linkedin
Dr Fiona McLaughlin
HOX Therapeutics Ltd
NED
HOX Therapeutics Ltd · Part-time
Dec 2023 - Present · 2 mos"
Good Morning , everyone seems to have an opinion , fair enough guess good fun pretending to be arcmchair CEO's .
Simple view : Avacta have a plan : "With a balanced business and capital allocation model: a high-value oncology pipeline supported by a revenue generating, fast-growing diagnostics business, Avacta seeks to create long-term shareholder value alongside patient benefit."
---" high-value oncology pipeline" will shortly be self financed .
---" fast-growing diagnostics business" will generate profitable revenues & add cash to Avacta coffers .
Happy to leave Avacta team get on with it . they certainly know much more than me how to run a business .
Shaeholder value give it another max 2.5 years , hopefully handsome investment return will happen long before then.
Good luck everyone .
Https://www.grandviewresearch.com/industry-analysis/stem-cells-market
"The global stem cells market size was valued at USD 14.80 billion in 2023 and is expected to grow at a compound annual growth rate (CAGR) of 11.43% from 2024 to 2030."
--------
AffyXell Platform Could end up being best in class "that the therapeutic effect was not only seen in the envelope but also in the organs. This is because there is a large unmet medical need that is not effective with antibody therapeutics or small molecule compounds. It showed the possibility of becoming the first causative treatment."
Good that Avacta have JV affimer assets
------------------
"CEO Jeon said, "Our short-term goal is to raise funds for technology development through Series B fundraising, and to achieve milestones such as IND success and technology exports," adding, "We would like to use these milestones as a springboard to successfully IPO to reward our shareholders and employees who believed in and invested in Apicell and our employees for their hard work."
---------
"-Last year, you announced the results of the PoC (Proof of Concept) efficacy evaluation of 'AFX001', what was the reaction from academia and industry?
"At conferences hosted by the International Society of Stem Cell Therapy (ISCT 2023), which is voted the most important conference in cell and gene therapy, and the Alliance for Regenerative Medicine (ARM), which plays an important role in the industry, the results of the AFX001 PoC were presented in Barcelona, Spain, Paris, France, and Houston, Texas, USA.
For those who are not stem cell researchers, they were very interested in the fact that Apicell therapy significantly lowered the clinical score (symptom severity) of acute graft-versus-host disease (GvHD) and that the therapeutic effect was not only seen in the envelope but also in the organs. This is because there is a large unmet medical need that is not effective with antibody therapeutics or small molecule compounds. It showed the possibility of becoming the first causative treatment.
In the case of stem cell researchers, they showed a lot of interest in Apicell's process and quality control technology. This is because it is something they have been thinking about for a long time. Those who have been doing stem cell research for a long time often expressed themselves as "smart" after listening to the presentation. Since the announcement, we have held partnering meetings with a number of biotechs, big pharma, and overseas VCs (venture capital) and are still in discussions."
-How was the recent pre-clinical trial planning meeting with the U.S. FDA?
"The biggest achievement of the FDA pre-meeting was the confirmation that Apicell's process and quality control system and data level conform to FDA standards. In fact, from the perspective of regulatory agencies, the main factor in evaluating cell and gene therapy products differently from other modalities is process development and quality control (CMC). In this respect, Apicell has achieved 100% of the desired outcomes at the first pre-IND meeting of the FDA."
Lot of info in that link worth a read.
https://news.bizwatch.co.kr/article/mobile/2024/01/24/0023
""Conceptually, of course, it's possible. Applying Apicell platform technology to cells that kill cancer cells or have the ability to immunomodulator cancer cells can be applied to develop breakthrough cancer treatments. However, at present, we are focusing on the development of immunological disease therapeutics that can be the first to take advantage of mesenchymal stem cells specialized in immunomodulatory. In the long term, it can be expanded to the development of cancer treatments."
- Is there a place where technology export is currently being discussed?
"We are in discussions with a number of companies on technology transfer and joint R&D. Recent trends show that technology transfer is actively taking place after IND. Apicell is also expected to have a technology export performance after the IND or before the IPO."
FYI Website update News coverage
https://news.bizwatch.co.kr/article/mobile/2024/01/24/0023
http://affyxell.com/bbs/?so_table=news&mode=VIEW&num=38&category=&findType=&findWord=&sort1=&sort2=&page=1
FDA Pre-Clinical Meeting..."100% Achieved"
"2026 IPO Plans... Technology exports are also discussed."
"When asked about the goals he wants to achieve at Apicell Therapeutics, Jeon Seung-ho, CEO of Daewoong Pharmaceutical, said, "We want to succeed in the IPO in 2026 and reward the shareholders who believed in and invested in Apicell and the executives and employees who worked hard." He said, "As the CEO who first planned the company, I want to see the company grow into a global unicorn company by becoming a Moderna for cell therapy for autoimmune diseases." /photo=Lee Myung-geun qwe123@"
Already have diagnostic test for measles
https://www.launchdiagnostics.com/product/measles-igg-kit/
FYI -- No change in Significant Shareholdings
https://avacta.com/investors/key-information/
----------------
"Significant Shareholdings
Current significant shareholders are as follows:
Conifer Management, LLC 4.4%
Baillie Gifford & Co Limited 3.7%
As at 22nd January 2024 the company has 287,956,207 ordinary shares of 10p each in issue.
1.5% of the ordinary shares of the Company are not held in public hands.
Https://twitter.com/Avacta
Avacta
@avacta
·
10m
We are pleased to have been selected for Singer Analysts' Best Ideas for 2024. #AVCT
Quote
Singer Capital Markets
@_singercm
·
19h
Singer Capital Markets Best Ideas 2024💡📈 – Report available now!
If you are a client of Singer Capital Markets under MiFiD and would like to receive our Best Ideas 2024, please get in touch:
FYI Benefit of LD proven company assets .
---------------------------
https://www.launchdiagnostics.com/product/mycoplasma-pneumonie-solutions/
Partner - ACCUSAY Diagnostics
Global Market https://www.grandviewresearch.com/industry-analysis/mycoplasma-testing-market
Linkedin https://www.linkedin.com/feed/update/urn:li:activity:7155237522585894912/
"Launch Diagnostics LimitedLaunch Diagnostics Limited
1,408 followers1,408 followers
11m • 11m •
With cases of Mycoplasma pneumoniae increasing globally, effective testing for this organism is of vital importance in patient care and management this respiratory season.
As a distributor for IVD products in the UK and Ireland, Launch Diagnostics and ACCUSAY Diagnostics are able to support your testing needs through supply of both Serology and Molecular based assays, alongside relevant QC material.
To learn about the range of products available, visit the link below, contact us at enquiries@launchdiagnostics.com or speak to your local territory manager.
https://lnkd.in/esU87B7n